Drugs / berahyaluronidase alfa-pmph
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | KEYTRUDA QLEX | — | 2025-09-19 | fda.gov ↗ |
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07822373 Background | Nov 2026 → Nov 2034 expected | infiltrating bladder urothelial carcinoma | University of Utah | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | berahyaluronidase alfa-pmph | “Subjects will receive one year of treatment with pembrolizumab IV or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) SC.” NCT07822373 ↗ |
| Route | Subcutaneous | “pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) SC” NCT07822373 ↗ |